Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
32 hedge funds and large institutions have $94.2M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
7% more capital invested
Capital invested by funds: $87.7M → $94.2M (+$6.56M)
11% less funds holding
Funds holding: 36 → 32 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$826K |
| 2 |
SC
Samlyn Capital
New York
|
+$526K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$206K |
| 4 |
JP Morgan Chase
New York
|
+$166K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$58.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$1.8M |
| 2 |
Walleye Capital
New York
|
-$389K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$311K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$263K |
| 5 |
Two Sigma Investments
New York
|
-$132K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Two Sigma Investments
New York
| $57K | -$132K | -37,405 | -73% |
|
27
Charles Schwab
San Francisco,
California
| $52K | – | – | – |
|
|
SSA
28
Schonfeld Strategic Advisors
New York
| $47K | -$35.6K | -10,100 | -47% |
|
29
Goldman Sachs
New York
| $42K | -$92 | -26 | -0.3% |
|
30
Citigroup
New York
| $29K | +$24.9K | +7,073 | New |
|
31
Osaic Holdings
Scottsdale,
Arizona
| $4K | +$3.53K | +1,000 | New |
|
|
GTC
32
Ghost Tree Capital
New York
| – | -$1.8M | -473,562 | Closed |
|
|
33
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$311K | -81,739 | Closed |
|
|
34
Russell Investments Group
London,
United Kingdom
| – | -$263K | -69,351 | Closed |
|
35
Fidelity Investments
Boston,
Massachusetts
| – | -$8K | -2,163 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$7K | -1,782 | Closed |
|
37
Wells Fargo
San Francisco,
California
| – | +$32 | +9 | +8% |
|
STSA Hedge Fund Activity: Q2 2022 in Review
32 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q2 2022, worth a combined $94.2M — up 7.5% from $87.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of STSA and 3 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Morgan Stanley, adding an estimated $826K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $1.8M sold.
- 32 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q2 2022, down from 36 in Q1 2022.
- Funds reported $94.2M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q2 2022, up 7.5% quarter-over-quarter.
- 3 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 7 closed out, a net change of -4 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Morgan Stanley, an estimated $826K added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Ghost Tree Capital, an estimated $1.8M sold.
Based on aggregated 13F filings for Q2 2022.